Impact ledger

Regeneron Pharmaceuticals, Inc. (REGN): the developments shaping its investment case

Follow the evidence affecting Regeneron Pharmaceuticals, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

Research Regeneron Pharmaceuticals, Inc. · $399/mo

Test assumptions, examine opportunities, and save your research.

Material developments

2026-09-06 · 6 reports

Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGR

Channel: Increased market size and demand for Dupixent (dupilumab), a leading biologic treatment for atopic dermatitis, directly boosting sales and market share.

Bullish· 3-12m

2026-09-16

Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy

Channel: Increased competition in the oncology market, particularly for melanoma, but also potential for broader validation of novel therapeutic approaches.

mixed· 3-12m

2026-09-24 · 3 reports

Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial

Channel: Increased competitive pressure in the kidney disease therapeutic area, potentially impacting future market share for existing or pipeline drugs.

Bearish· 3-12m

Event impact log

18 events mapped to REGN since 2026-09-06. Evidence through 2026-09-28.

Date	Event	Channel	Direction	Horizon	Impact
2026-09-28	Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation	Competitive landscape dynamics, R&D strategy, and investor sentiment towards GLP-1 market participants.	watch	3-12m	0.20
2026-09-28	Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise lead	Competitive landscape, investor perception of pipeline strength in obesity/metabolic disorders.	mixed	3-12m	0.20
2026-09-28	Eli Lilly Discontinues Early-Stage GLP-1 Candidate Following Efficacy Review	Reduced potential future competition in the GLP-1 market; relative strengthening of other pipeline candidates.	Bullish	1-3m	0.10
2026-09-28	Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of Sales	Competitive landscape, R&D pipeline comparison	Bullish	3-12m	0.20
2026-09-27	Eli Lilly Drops Experimental Obesity Candidate While Core GLP-1s Exceed 65% of Revenue	Similar to AMGN, the event could lead to increased investor scrutiny on the obesity drug pipeline and R&D efficiency across the industry, affecting companies with metabolic assets.	watch	3-12m	0.20
2026-09-27	Hangzhou Global Open-Source AI Finals Conclude with 1M RMB Biotech Prize	Open-source AI advancements in peptide and therapeutic design could enhance drug discovery pipelines, potentially leading to more efficient R&D, faster identification of drug candidates, and reduced development costs for biotech companies like Regeneron.	Bullish	1-5y	0.30
2026-09-24	Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial	Increased competitive pressure in the kidney disease therapeutic area, potentially impacting future market share for existing or pipeline drugs.	Bearish	3-12m	0.30
2026-09-24	Vertex reports positive Phase IIb inaxaplin results for kidney disease	Indirect competitive pressure in kidney disease treatments, potential for future pipeline shifts.	watch	1-5y	0.30
2026-09-24	Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD	Indirect competitive pressure or market sentiment shift in the rare kidney disease space. Potential for increased investor scrutiny on competing pipeline assets.	watch	3-12m	0.25
2026-09-24	Vertex Reports Positive Phase IIb Kidney Disease Data for Inaxaplin	Potential competitive pressure in the kidney disease therapeutic area, though direct overlap with APOL1-mediated disease is limited.	watch	3-12m	0.30
2026-09-17	Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Telomir-Zn Preclinical Research in AMD	Potential long-term competitive threat in the AMD market, though highly speculative at preclinical stage.	watch	1-5y	0.10
2026-09-16	Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy	Increased competition in the oncology market, particularly for melanoma, but also potential for broader validation of novel therapeutic approaches.	mixed	3-12m	0.40
2026-09-06	Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGR	Increased market size and demand for Dupixent (dupilumab), a leading biologic treatment for atopic dermatitis, directly boosting sales and market share.	Bullish	3-12m	0.80
2026-09-06	Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand	Increased demand and market size for Dupixent (dupilumab), a leading biologic for atopic dermatitis, directly boosting sales.	Bullish	1-5y	0.80
2026-09-06	Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics	Direct increase in market opportunity for Dupixent (co-developed with Sanofi), a leading biologic in atopic dermatitis. Increased sales volume and potential for price stability/growth.	Bullish	3-12m	0.85
2026-09-06	Atopic Dermatitis Market Projected to Reach $33.4B by 2035 on Biologics Expansion	Increased market size and demand for Dupixent (biologic) in atopic dermatitis.	Bullish	1-5y	0.80
2026-09-06	Atopic Dermatitis Biopharma Market Projected to Reach $33.4B by 2035 at 7.7% CAGR	Increased market size and demand for Dupixent (dupilumab), a leading biologic for atopic dermatitis, directly boosting sales and market share.	Bullish	3-12m	0.80
2026-09-06	Atopic Dermatitis Market Projected to Reach $33.4B by 2035 on Biologics Growth	Increased market size and adoption for Dupixent (co-marketed with Sanofi), a leading biologic for atopic dermatitis.	Bullish	1-5y	0.80

Continue this research

Build your Regeneron Pharmaceuticals, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.